Decreased lymphocyte counts and serum immunoglobulin levels were seen in patients irrespective of ribosomal protein genotype and steroid treatment.
Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.
Researchers assessed the predictive value of various laboratory parameters for iron overload in patients with congenital hemolytic anemias.
Treatment with erythropoietin-stimulating agents may yield improved hematopoietic responses and reduce the need for red blood cell transfusions.
Of 20 patients who showed response to eltrombopag at 24 weeks, 25% had not shown response at 12 weeks.
A multidisciplinary intervention strategy led to a 61% decrease in hospital stay duration for patients with sickle cell disease and vaso-occlusive pain.
Anemia in patients with atrial fibrillation is associated with major bleeding and lower time in therapeutic range.
Quantitative sensory testing may facilitate objective evaluation of feelings of pain and function in patients with sickle cell disease.
Immune checkpoint inhibitor (ICI) therapy may lead to autoimmune hemolytic anemia (AIHA), but diagnosis of AIHA may not necessitate ICI discontinuation.
Mometasone usage was found to correlate with decreased levels of macrophage markers but not of asthma-related markers.
Infants with sickle cell disease who started hydroxyurea before 12 months of age had better long-term outcomes.
Patients with iron deficiency anemia who were treated with intravenous iron experienced significant changes in parameters measuring coagulability.
Despite deeper understanding of some of the molecular mechanisms underlying Diamond-Blackfan anemia, the search for effective therapies is ongoing.
A set of diagnostic criteria for defining the types of acute pain observed in patients with sickle cell disease was formulated by a multi-institutional panel of experts.
The use of a less toxic conditioning regimen may establish bone marrow transplantation as a preferred therapeutic alternative for adults with sickle cell disease.
Patients who received sutimlimab experienced meaningful increases in hemoglobin levels and normalization of bilirubin levels.
Novartis announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for crizanlizumab (SEG101) for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease.
A systematic literature review showed that erythropoietin-stimulating agents positively influenced outcomes of patients with MDS-associated anemia.
The long-term outcomes of limiting the frequency of red blood cell transfusions in patients with anemia had not previously been described.
Researchers developed a new method to measure single cell red blood cell deformability.
Researchers assessed 266 pregnant women with and without sickle cell disease in Ghana to determine the effect of a multidisciplinary care strategy.
In addition to the 1000mg tablet, Siklos is also available in 100mg tablets.
The approval was based on data from a single-arm, open-label sequential cohort study in which patients received Promacta in combination with horse antithymocyte globulin (h-ATG) and cyclosporine.
Allogeneic hematopoietic cell transplantation was tolerated well by pediatric patients with sickle cell disease and transfusion-dependent thalassemia.
Results from a study in which patients with Fanconi anemia underwent a reduced intensity conditioning regimen followed by bone marrow transplantation.
Eltrombopag plus IST was compared with IST alone in a simulated population of 1 million patients with severe aplastic anemia.
The efficacy, safety, and feasibility of using hydroxyurea as a therapeutic agent for sickle cell anemia have not been assessed in many populations.
Investigators conducted a systematic review of 7083 studies to evaluate the association between sickle cell trait and any of 24 adverse clinical outcomes.
Children born with sickle cell disease in low-resource regions of the world often remain undiagnosed and therefore do not receive appropriate treatment.
Retacrit will be priced 57.1% below the Wholesale Acquisition Cost (WAC) of Procrit and 33.5% below the WAC of Epogen, at $11.03 per 1000 Units/mL.
More than one-third of nonanemic patients admitted to Royal Perth Hospital in Australia developed anemia during their stay.
Researchers analyzed prospective follow-up data from 702 patients with Diamond-Blackfan anemia for cancer incidence and risk.
Eculizumab has been used to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Complications in older patients with sickle cell disease are sometimes misattributed to their disease, possibly delaying appropriate diagnosis and treatment.
Approximately 1 in 500 African Americans in the United States has sickle cell disease.
Hydroxyurea, an antimetabolite, is thought to cause an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein.
Anemia with a baseline hemoglobin <13 g/dL was associated with a more than 5-fold increased risk for contrast-induced acute kidney injury in patients undergoing coronary angiography.
The approval of Retacrit was based on a review of evidence that included human pharmacokinetic/pharmacodynamic data and clinical immunogenicity data which demonstrated a high degree of similarity between Retacrit and its reference product.
Using the infarct heat map, the investigators determined that infarct density was higher in the deep white matter and co-localized with the elevated OEF region in the independent prospective cohort.
In this post hoc analysis, researchers explored whether anemia was a predictor of radiographic progression in patients with RA who were treated with tofacitinib.
The researchers found that OS was superior in IST responders. Shorter relapse-free survival (RFS) was seen with partial response to IST compared with complete response.
Other biologic DMARDs were not associated with any significant clinically meaningful increase in Hb and Hct levels.
Low hemoglobin levels independently predicted all-cause, cardiovascular, and noncardiovascular mortality in patients with coronary artery disease.
Patients with sickle cell disease may have a unique cardiomyopathy with restrictive physiology.
Treatment of iron deficiency anemia was linked to improvements in vitamin B12, folate and lipids.